Amneal Pharmaceuticals (NASDAQ:AMRX) Announces Earnings Results, Beats Expectations By $0.05 EPS

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) released its quarterly earnings results on Friday. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.05, Zacks reports. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. The business had revenue of $695.42 million for the quarter, compared to the consensus estimate of $714.78 million. Amneal Pharmaceuticals updated its FY 2025 guidance to 0.650-0.70 EPS.

Amneal Pharmaceuticals Price Performance

Shares of AMRX stock traded up $0.03 during trading hours on Wednesday, reaching $7.21. 736,036 shares of the company's stock were exchanged, compared to its average volume of 1,421,901. The company's 50 day moving average is $7.98 and its two-hundred day moving average is $8.15. The company has a market cap of $2.23 billion, a P/E ratio of -10.60 and a beta of 1.17. Amneal Pharmaceuticals has a 1 year low of $6.29 and a 1 year high of $9.48.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on AMRX shares. StockNews.com upgraded shares of Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Monday. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $9.00 to $12.00 in a research report on Monday, February 24th. Finally, Barclays raised their price target on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a report on Monday, March 3rd. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $11.50.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the business's stock in a transaction on Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the sale, the insider now directly owns 48,578,209 shares in the company, valued at approximately $405,628,045.15. The trade was a 9.33 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.90, for a total value of $712,000.00. Following the transaction, the director now owns 1,808,886 shares of the company's stock, valued at $16,099,085.40. This represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 26.56% of the stock is owned by corporate insiders.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.